Evidence map›Paper›PMID 39620193›Full record

ArticleJournal of the ASEAN Federation of Endocrine Societies2024

Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults With Type 2 Diabetes in the Philippines: Results from a Prospective, Non-interventional, Real-World Study.

Nemencio Nicodemus, Nerissa Ang-Golangco, Grace Aquitania, Gregory Joseph Ryan Ardeña, Oliver Allan Dampil, Richard Elwyn Fernando, Nicole-Therese Flor, Sjoberg Kho, Roberto Mirasol, Araceli Panelo and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the ASEAN Federation of Endocrine Societies, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Nemencio NicodemusManila Doctors Hospital, Manila, Philippines.
Nerissa Ang-GolangcoMakati Medical Center, Makati, Philippines.
Grace AquitaniaDavao Doctors Hospital, Davao, Philippines.
Gregory Joseph Ryan ArdeñaPanay Health Care Multi-Purpose Cooperative Hospital, Kalibo, Philippines.
Oliver Allan DampilProvidence Hospital, Quezon City, Philippines.
Richard Elwyn FernandoSaint Luke's Medical Center, Quezon City, Philippines.
Nicole-Therese FlorNovo Nordisk Philippines, Taguig City, Philippines.
Sjoberg KhoUniversity of Santo Tomas Hospital, Manila, Philippines.
Roberto MirasolManila Doctors Hospital, Manila, Philippines.
Araceli PaneloUniversity of the East Ramon Magsaysay Memorial Medical Center, Quezon City, Philippines.
Francis PasaporteFancom Medical Plaza and Diagnostics, Iloilo City, Philippines.
Mercerose Puno-RocamoraNovo Nordisk Philippines, Taguig City, Philippines.
Ahsan ShoebNovo Nordisk Philippines, Taguig City, Philippines.
Marsha TolentinoPerpetual Succour Hospital, Cebu, Philippines.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Blood glucose levels of the majority of Filipino patients with type 2 diabetes (T2D) remain uncontrolled. Insulin degludec/insulin aspart (IDegAsp) is a fixed-ratio co-formulation of the long-acting basal insulin degludec and the rapidacting prandial insulin aspart. The real-world ARISE (A Ryzodeg Methodology: This 26-week, open-label, non-interventional study examined outcomes in adults with T2D initiating or switching to IDegAsp (N=185) from other antidiabetic treatments per local clinical guidance. Results: Compared with the baseline, there was a significant improvement in glycated hemoglobin at the end of the study (EOS) (estimated difference [ED] -1.4% [95% confidence interval -1.7, -1.1]; Conclusion: Initiating or switching to IDegAsp was associated with improved glycemic control, lower body weight, and lower HRU for people with T2D in the Philippines. No new, unexpected AEs were reported.

Indexed as

Blood GlucoseDiabetes Mellitus, Type 2Drug CombinationsGlycated HemoglobinHypoglycemic AgentsInsulin, Long-ActingAdultAgedDrug SubstitutionFemaleHumansMaleMiddle AgedPhilippinesProspective StudiesTreatment OutcomeBlood GlucoseDrug CombinationsGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic Agentsinsulin degludec, insulin aspart drug combinationInsulin, Long-Actinginsulin aspart;insulin aspart drug combination;insulin degludectype 2 diabetes

Identifiers

PMID39620193
PMCPMC11604473

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.